Role of dopamine agonists in Parkinson's disease: An update

Expert Review of Neurotherapeutics

Volumn 7, Issue 10, 2007, Pages 1391-1399

  Bonuccelli, Ubaldo ^a   Pavese, Nicola ^b  

^a UNIVERSITY OF PISA   (Italy)

^b MEDICAL RESEARCH COUNCIL   (United Kingdom)

Author keywords

Apomorphine; Cabergoline; Dopamine agonists; Parkinson's disease; Pergolide; Pramipexole; Ropinirole; Rotigotine

Indexed keywords

[2 [[2 [[[3 (4 CHLOROPHENYL) 8 METHYL 8 AZABICYCLO[3.2.1]OCT 2 YL]METHYL](2 MERCAPTOETHYL)AMINO]ETHYL]AMINO]ETHANETHIOLATO]OXOTECHNETIUM TC 99M; APOMORPHINE; BROMOCRIPTINE; CABERGOLINE; DOMPERIDONE; DOPAMINE RECEPTOR STIMULATING AGENT; FENFLURAMINE; LEVODOPA; LISURIDE; MODAFINIL; PERGOLIDE; PIRIBEDIL; PLACEBO; PRAMIPEXOLE; ROPINIROLE; ROTIGOTINE;

APOPTOSIS; APPLICATION SITE REACTION; CLINICAL TRIAL; CONTINUOUS INFUSION; DAYTIME SOMNOLENCE; DELUSION; DIZZINESS; DOSE RESPONSE; DRUG DOSE INCREASE; DRUG DOSE REDUCTION; DRUG DOSE TITRATION; DRUG EFFICACY; DRUG MECHANISM; DRUG METABOLISM; DRUG RELEASE; DRUG SAFETY; DRUG SUBSTITUTION; DRUG WITHDRAWAL; DYSKINESIA; FIBROSIS; HALLUCINATION; HUMAN; LIPID PEROXIDATION; MONOTHERAPY; MOOD CHANGE; NAUSEA; NEUROPROTECTION; NONHUMAN; ORTHOSTATIC HYPOTENSION; PARANOIA; PARKINSON DISEASE; PATHOLOGICAL GAMBLING; PERIPHERAL EDEMA; REVIEW; SIDE EFFECT; SOMNOLENCE; VALVULAR HEART DISEASE; VIVID DREAM; VOMITING;

ANTIPARKINSON AGENTS; DOPAMINE AGONISTS; DRUG ADMINISTRATION ROUTES; HUMANS; PARKINSON DISEASE;

EID: 35548949458     PISSN: 14737175     EISSN: 17448360     Source Type: Journal    
DOI: 10.1586/14737175.7.10.1391     Document Type: Review

References (81)

1. Obeso JA, Rodriguez-Oroz MC, Rodriguez M et al. The basal ganglia and disorders of movement: pathophysiological mechanisms. News Physiol. Sci. 17, 51-55 (2002).
2. Pavese N, Evans AH, Tai YF et al. Clinical correlates of levodopa-induced dopamine release in Parkinson disease: a PET study. Neurology 67(9), 1612-1617 (2006).
3. Calne DB. Treatment of Parkinson's disease. N. Engl. J. Med. 30(14), 1021-1027 (1993).
4. Bennett JP Jr, Piercey MF. Pramipexole - a new dopamine agonist for the treatment of Parkinson's disease. J. Neurol. Sci. 163(1), 25-31 (1999).
5. Jenner P. A novel dopamine agonist for the transdermal treatment of Parkinson's disease. Neurology 65(2 Suppl. 1), S3-S5 (2005).
6. Bonuccelli U. Comparing dopamine agonists in Parkinson's disease. J. Neurol. Sci. 16(Suppl. 1), S13-S19 (2003).
7. Canesi M, Antonini A, Mariani CB et al. An overnight switch to ropinirole therapy in patients with Parkinson's disease. J. Neural Transm. 106, 925-929 (1999).
8. Ulm G, Schuler P. For the MODAC Study Group. Cabergoline versus pergolide: a video-blinded, randomized, multicenter cross-over study. Akt. Neurologie 25, 360-365 (1999).
9. Hanna PA, Ratkos L, Ondo et al. Switching from pergolide to pramipexole in patients with Parkinson's disease. J. Neural Transm. 108, 63-70 (2001).
10. Kartzinel R, Teychenne P, Gillespie MM et al. Bromocriptine and levodopa (with or without carbidopa) in parkinsonism. Lancet 2(7980), 272-275 (1976).
11. Lieberman AN, Kupersmith M, Gopinathan G et al. Bromocriptine in Parkinson disease: further studies. Neurology 29(3), 363-369 (1979).
12. McDonald RJ, Horowski R. Lisuride in the treatment of parkinsonism. Eur. Neurol. 22(4), 240-255 (1983).
13. Olanow CW, Fahn S, Muenter M et al. A multicenter double-blind placebo-controlled trial of pergolide as an adjunct to Sinemet in Parkinson's disease. Mov. Disord. 9(1), 40-47 (1994).
14. Hutton JT, Morris JL, Brewer MA. Controlled study of the antiparkinsonian activity and tolerability of cabergoline. Neurology 43(3), 613-616 (1993).
15. Lieberman A, Ranhosky A, Korts D. Clinical evaluation of pramipexole in advanced Parkinson's disease: results of a double-blind, placebo-controlled, parallel-group study. Neurology 49(1), 162-168 (1997).
16. Lieberman A, Olanow CW, Sethi K et al. A multicenter trial of ropinirole as adjunct treatment for Parkinson's disease. Ropinirole Study Group. Neurology 51(4), 1057-1062 (1998).
17. Rascol O, Lees AJ, Senard JM et al. A placebo-controlled study of ropinirole, a new D2 agonist, in the treatment of motor fluctuations of L-DOPA-treated parkinsonian patients. Adv. Neurol. 69, 531-534 (1996).
18. Facca A, Sanchez-Ramos J. High-dose pergolide monotherapy in the treatment of severe levodopa-induced dyskinesias. Mov. Disord. 11(3), 327-329 (1996).
19. Cristina S, Zangaglia R, Mancini F et al. High dose ropinirole in advanced Parkinson's disease with severe dyskinesias. Clin. Neuropharmacol. 26(3), 146-150 (2003).
20. Odin P, Oehlwein C, Storch A et al. Efficacy and safety of high-dose cabergoline in Parkinson's disease. Acta Neurol. Scand. 113(1), 18-24 (2006).
21. Rinne UK, Bracco F, Chouza C et al. Cabergoline in the treatment of early Parkinson's disease: results of the first year of treatment in a double-blind comparison of cabergoline and levodopa. The PKDS009 Collaborative Study Group. Neurology 48(2), 363-368 (1997).
22. Barone P, Bravi D, Bermejo-Pareja F et al. Pergolide monotherapy in the treatment of early Parkinson's disease. A randomized controlled study. Neurology 53, 573-599 (1999).
23. Montastruc JL, Rascol O, Senard JM et al. A randomised controlled study comparing bromocriptine to which levodopa was later added, with levodopa alone in previously untreated patients with Parkinson's disease: a five year follow up. J. Neurol. Neurosurg. Psychiatr. 57(9), 1034-1038 (1994).
24. Shannon KM, Bennett JP, Friedman JH for the Pramipexole Study Group. Efficacy of pramipexole, a novel dopamine agonist, as monotherapy in mild to moderate Parkinson's disease. Neurology 49, 724-728 (1997).
25. Adler CH, Sethi KD, Hauser RA et al. Ropinirole for the treatment of early Parkinson's disease. The Ropinirole Study Group. Neurology 49, 393-399 (1997).
26. Rascol O, Brooks DJ, Korczyn AD et al. A five-year study of the incidence of dyskinesia in patients with early Parkinson's disease who were treated with ropinirole or levodopa. (056 Study Group). N. Engl. J. Med. 342(20), 1484-1491 (2000).
27. Parkinson Study Group. Pramipexole vs levodopa as initial treatment for Parkinson disease: a randomized controlled trial. JAMA 284(15), 1931-1938 (2000).
28. Bracco F, Battaglia A, Chouza C et al. PKDS009 Study Group. Long-acting dopamine receptor agonist cabergoline in early Parkinson's disease: final results of a 5-year, double-blind, levodopa-controlled study. CNS Drugs 18(11), 733-746 (2004).
29. Oertel WH, Wolters E, Sampaio C, et al. Pergolide versus levodopa monotherapy in early Parkinson's disease patients: the PELMOPET study. Mov. Disord. 21, 343-353 (2006).
30. Parkinson Study Group. Dopamine transporter brain imaging to assess the effects of pramipexole vs levodopa on Parkinson disease progression. JAMA 287(13), 1653-1661 (2002).
31. Rinne UK. Early combination of bromocriptine and levodopa in the treatment of Parkinson's disease: a 5-year follow-up. Neurology 37(5), 826-828 (1987).
32. Thomas A, Bonanni L, Iorio AD et al. End-of-dose deterioration in non-ergolinic dopamine agonist monotherapy of Parkinson's disease. J. Neurol. 253(12), 1633-1639 (2006).
33. Thobois S. Proposed dose equivalence for rapid switch between dopamine receptor agonists in Parkinson's disease: a review of the literature. Clin. Ther. 29, 112-125 (2006).
34. Goetz CG, Blasucci L, Stebbins GT. Switching dopamine agonists in advanced Parkinson's disease. Is rapid titration preferable to slow? Neurology 52, 1227-1229 (1999).
35. Patton G, Neilson S, Boroojerdi B. Tolerability of switching from an oral dopamine agonist to transdermal rotigotine in Parkinson's disease. Presented at: The First World Parkinson Congress. Washington DC, USA, 22-26 February 2006.
36. Stocchi F, Vacca L, Berardelli A et al. Dual dopamine agonist treatment in Parkinson's disease. J. Neurol. 250(7), 822-826 (2003).
37. The Parkinson Study Group. A controlled trial of rotigotine monotherapy in early Parkinson's disease. Arch. Neurol. 60(12), 1721-1728 (2003).
38. Watts RL, Jankovic J, Waters C et al. Randomized, blind, controlled trial of transdermal rotigotine in early Parkinson disease. Neurology 68(4), 272-276 (2007).
39. Jankovic J, Watts RL, Martin W et al. Transdermal rotigotine: double-blind, placebo-controlled trial in Parkinson disease. Arch. Neurol. 64(5), 676-682 (2007).
40. LeWitt PA, Lyons KE, Pahwa R. SP 650 Study Group. Advanced Parkinson disease treated with rotigotine transdermal system: PREFER Study. Neurology 68(16), 1262-1267 (2007).
41. Poewe WH, Rascol O, Quinn N et al. SP 515 Investigators. Efficacy of pramipexole and transdermal rotigotine in advanced Parkinson's disease: a double-blind, double-dummy, randomised controlled trial. Lancet Neurol. 6, 513-520 (2007).
42. Factor SA. Intermittent subcutaneous apomorphine therapy in Parkinson's disease. Neurology 62(Suppl. 4), 12-17 (2004).
43. Colzi A, Turner K, Lees AJ. Continuous subcutaneous waking day apomorphine in the long term treatment of levodopa induced interdose dyskinesia in Parkinson's disease. J. Neurol. Neurosur. Psychiatr. 64, 573-576 (1998).
44. Katzenschlager R, Hughes A, Evans A et al. Continuous sc apomorphine therapy improves dyskinesias in Parkinson's disease: a prospective study using single-dose challenges. Mov. Disord. 20(2), 151-157 (2005).
45. Stocchi F, Ruggieri S, Vacca L et al. Prospective randomized trial of lisuride infusion versus oral levodopa in patients with Parkinson's disease. Brain 125, 2058-2066 (2002).
46. Pahwa R, Stacy MA, Factor SA et al. EASE-PD Adjunct Study Investigators. Ropinirole 24 h prolonged release: randomized, controlled study in advanced Parkinson disease. Neurology 68(14), 1108-1115 (2007).
47. Bonuccelli U, Pavese N. Dopamine agonists in the treatment of Parkinson's disease. Expert Rev. Neurother. 6(1), 81-89 (2006).
48. Carter AJ, Muller RE. Pramipexole, a dopamine D2 autoreceptor agonist, decreases the extracellular concentration of dopamine in vivo. Eur. J. Pharmacol. 200(1), 65-72 (1991).
49. Uberti D, Carsana T, Francisconi S et al. A novel mechanism for pergolide-induced neuroprotection: inhibition of NF-eκB nuclear translocation. Biochem. Pharmacol. 67(9), 1743-1750 (2004).
50. Gu M, Iravani MM, Cooper JM et al. Pramipexole protects against apoptotic cell death by non-dopaminergic mechanisms. J. Neurochem. 91(5), 1075-1081 (2004).
51. Kitamura Y, Kosaka T, Kakimura JI et al. Protective effects of the antiparkinsonian drugs talipexole and pramipexole against 1-methyl-4- phenylpyridinium-induced apoptotic death in human neuroblastoma SH-SY5Y cells. Mol. Pharmacol. 54(6), 1046-1054 (1998).
52. Rodriguez MC, Obeso JA, Olanow CW. Subthalamic nucleus-mediated excitotoxicity in Parkinson's disease: a target for neuroprotection. Ann. Neurol. 44(Suppl. 1), S175-S188 (1998).
53. Hurelbrink CB, Barker RA. Prospects for the treatment of Parkinson's disease using neurotrophic factors. Expert Opin. Pharmacother. 2(10), 1531-1543 (2001).
54. Scheller D, Chan P, Li Q et al. Rotigotine treatment partially protects from MPTP toxicity in a progressive macaque model of Parkinson's disease. Exp. Neurol. 203(2), 415-422 (2007).
55. Muller T, Fritze J. Fibrosis associated with dopamine agonist therapy in Parkinson's disease. Clin. Neuropharmacol. 26(3), 109-111 (2003).
56. McElvaney NG, Wilcox PG, Churg A et al. Pleuropulmonary disease during bromocriptine treatment of Parkinson's disease. Arch. Intern. Med. 148, 2231-2236 (1988).
57. Pritchett AM, Morrison JF, Edwards WD et al. Valvular heart disease in patients taking pergolide. Mayo Clin. Proc. 77(12), 1280-1286 (2002).
58. Van Camp G, Flamez A, Cosyns B et al. Heart valvular disease in patients with Parkinson's disease treated with high dose pergolide. Neurology 61, 859-861 (2003).
59. Zanettini R, Antonini A, Gatto G et al. Valvular heart disease and the use of dopamine agonists for Parkinson's disease. N. Engl. J. Med. 356(1), 39-46 (2007).
60. Schade R, Andersohn F, Suissa S et al. Dopamine agonists and the risk of cardiac-valve regurgitation. N. Engl. J. Med. 356(1), 29-38 (2007).
61. Junghanns S, Fuhrmann JT, Simonis G et al. Valvular heart disease in Parkinson's disease patients treated with dopamine agonists: a reader-blinded monocenter echocardiography study. Mov. Disord. 22(2), 234-238 (2007).
62. Connolly HM, Crary JL, McGoon MD et al. Valvular heart disease associated with fenfluramine-phentermine. N. Engl. J. Med. 337, 581-588 (1997).
63. Botero M, Fuchs R, Paulus DA et al. Carcinoid heart disease: a case report and literature review. J. Clin. Anesth. 14(1), 57-63 (2002).
64. Redfield MM, Nicholson WJ, Edwards WD et al. Valve disease associated with ergot-derivates alkaloid use: echocardiographic and pathologic correlations. Ann. Intern. Med. 117, 50-52 (1992).
65. 2B receptors in the cardiac valvulopathy associated with fenfluramine and other serotonergic medications. Circulation 102, 2836-2841 (2000).
66. 2B receptor activation plays crucial role. Mov. Disord. 19(12), 1523-1524 (2004).
67. 2, receptor subtypes. J. Pharmacol. Exp. Ther. 303(2), 815-822 (2002).
68. Frucht SJ, Greene PE, Fahn S. Sleep episodes in Parkinson's disease: a wake-up call. Mov. Disord. 15, 601-603 (2000).
69. Cantor CR, Stern MB. Dopamine agonists and sleep in Parkinson's disease. Neurology 58(Suppl. 1), S71-S78 (2002).
70. Korner Y, Meindorfner C, Moller JC et al. Predictors of sudden onset of sleep in Parkinson's disease. Mov. Disord. 19, 1298-1305 (2004).
71. Avorn J, Schneeweiss S, Sudarsky LR et al. Sudden uncontrollable somnolence and medication use in Parkinson disease. Arch. Neurol. 62, 1242-1248 (2005).
72. Gjerstad MD, Alves G, Wentzel-Larsen T et al. Excessive daytime sleepiness in Parkinson disease: is it the drugs or the disease? Neurology 67(5), 853-858 (2006).
73. Hogl B, Saletu M, Brandauer E et al. Modafinil for the treatment of daytime sleepiness in Parkinson's disease: a double-blind, randomized, crossover, placebo-controlled polygraphic trial. Sleep 25(8), 905-909 (2002).
74. Adler CH, Caviness JN, Hentz JG et al. Randomized trial of modafinil for treating subjective daytime sleepiness in patients with Parkinson's disease. Mov. Disord. 18(3), 287-293 (2003).
75. Dodd ML, Klos KJ, Bower JH, et al. Pathological gambling caused by drugs used to treat Parkinson disease. Arch. Neurol. 62(9), 1377-1381 (2005).
76. Grosset KA, Macphee G, Pal G et al. Problematic gambling on dopamine agonists: not such a rarity. Mov. Disord. 21(12), 2206-2208 (2006).
77. Drapier D, Drapier S, Sauleau P et al. Pathological gambling secondary to dopaminergic therapy in Parkinson's disease. J. Psychiatry Res. 144(2-3), 241-244 (2006).
78. Avanzi M, Baratti M, Cabrini S et al. Prevalence of pathological gambling in patients with Parkinson's disease. Mov. Disord. 21(12), 2068-2072 (2006).
79. Voon V, Hassan K, Zurowski M et al. Prospective prevalence of pathologic gambling and medication association in Parkinson disease. Neurology 66(11), 1750-1752 (2006).
80. Voon V, Thomsen T, Miyasaki JM et al. Factors associated with dopaminergic drug-related pathological gambling in Parkinson disease. Arch. Neurol. 64(2), 212-216 (2007).
81. Foley P, Gerlach M, Double KL et al. Dopamine receptor agonists in the therapy of Parkinson's disease. J. Neural Transm. 111(10-11), 1375-1446 (2004).